A committee of Japan's health ministry has approved US biotechnology company Novavax Inc's (Nasdaq:NVAX) COVID-19 vaccine, Reuters news agency reported on Monday.
If granted full approval, this will be Japan's fourth COVID-19 vaccine.
The Japanese government has reportedly agreed to purchase 150 million doses of Novavax's recombinant protein type vaccine, which will be manufactured in Japan by Takeda Pharmaceutical Co (Tokyo:4502).
So far, most of Japan's COVID-19 vaccinations have been carried out with the mRNA vaccines made by US pharmaceutical companies Pfizer Inc (NYSE:PFE) and Moderna Inc (Nasdaq:MRNA).
The vaccine from British pharmaceutical company Astrazeneca plc (LON:AZN) has also been approved, but most domestically produced supplies have not been used in Japan and instead donated overseas.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine